Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
246 Cards in this Set
- Front
- Back
METRONIDAZOLE MOA
|
Nitro group serves as an electron acceptor (reduced) → forms ROS → cell death
|
|
METRONIDAZOLE SPECTRUM / USE
|
GGETBaC
DOC: Entamoeba histolytica Giardia lamblia Trichomonas vaginalis |
|
METRONIDAZOLE IS USUALLY GIVEN WITH THIS LUMINAL AMEBICIDE DRUG. --> WHY?
|
Diloxanide furoate 90% cure rate
|
|
BECAUSE OF ITS METABOLISM BE CAUTIOUS IF GIVING METRONIDAZOLE TO PTS WITH ________ BECAUSE THE DRUG ACCUMULATES THERE
|
LIVER DISEASE
|
|
METRONIDAZOLE SE
|
*DISULFIRAM- LIKE RXN
*METALLIC TASTE IN MOUTH |
|
Diloxanide furoate can only be obtained by _______ WHAT IS ITS ONLY INDICATION?
|
can only get it from CDC. ONLY USED TO TREAT INTESTINAL AMEBIASIS
|
|
Diloxanide furoate S.E.
|
MILD - FLATULENCE
|
|
name 1 Systemic amebicide
|
Chloroquine
|
|
Primaquine WHAT TYPE OF DRUG, IS ONLY EFFECTIVE AGAINST THIS FORM ___
|
MALARIA DRUG EXOERYTHROCYTIC FORMS (malaria not inside RBC = tissue schizont)
|
|
Primaquine MOA
|
ACTS AS AN OXIDANT WHICH MAY CAUSE ITS SIDE EFFECTS
|
|
Primaquine SE WHICH OCCURS MOST COMMONLY IN THESE PTS
|
DRUG INDUCED HEMOLYTIC ANEMIA, IN PTS WITH LOW LEVELS OF G6PD (glucose-6-phosphate dehydrogenase).
|
|
Chloroquine GIVE ALL 4 MOA
|
1) In RBC, interferes with heme polymerase → soluble heme (TOXIC) kills parasite.
2) Binds ferriprotoporphyrin 9→ damages RBC membrane →RBC & parasite lysis. 3) Alkalinization of food vacuole→ prevents parasite heme digestion 4) ↓ DNA synthesis |
|
Chloroquine TYPE / USE (2)
|
Blood schizonticide
DOC FOR PLASMODIUM FALCIPARUM & Systemic amebicide |
|
Chloroquine SE
|
QUINIDINE EFFECT (ECG changes), chronic Tx = discolor nail beds, and visual disturbances
|
|
Quinine TYPE / USE
|
(Cinchona alkaloid) - Blood schizonticide; Chloroquine-resistant acute malaria
|
|
Quinine GIVE ALL 3 MOA
|
1) Inhibits heme polymerase
2) Damages membrane 3) Affects DNA synthesis |
|
Quinine SE
|
Cinchonism: nausea, vomiting, tinnitus, vertigo (reversible). Potentiation of neuromuscular blocking agents
|
|
Mefloquine TYPE
|
Blood Schizonticide
|
|
Mefloquine MOA / BEST ADVANTAGE
|
Damages parasite→ membrane
T1/2 = 17 DAYS (GIVEN ONCE WEEKLY) |
|
Mefloquine
-SE -CAUTION IN THESE PTS |
CNS: dizziness, disorientation, hallucinations
(caution to scuba divers). |
|
WHAT DO YOU GIVE FOR MALARIA PROPHYLAXIS?
|
Chloroquine
|
|
Melarsoprol
MOA |
Reacts with sulfhydryl group of enzymes in organism & host
|
|
Melarsoprol
USE |
DOC: late-stage T. brucei gambiense & rhodesiense with CNS involvement.
|
|
Melarsoprol
SE |
CNS: encephalopathy
|
|
Pentamidine isethionate
MOA |
Binds to parasite’s DNA
→ interferes with synthesis of DNA, RNA proteins. |
|
Pentamidine isethionate
USE / NOT EFFECTIVE AGAINST _____ |
T. brucei gambiense during hematological stage & Pneumocystis carinii
NOT effective against T. cruzi. |
|
Pentamidine isethionate CANNOT BE GIVEN ___ BECAUSE ____
|
DO NOT give IV
causes tachycardia, ↓↓↓ BP |
|
Pentamidine isethionate
SE |
**Toxicity to β cells of pancreas
Renal dysfunction (reversible). Hypotension |
|
Pentamidine isethionate
KINETICS |
DOES NOT ENTER CNS
|
|
Nifurtimox
MOA |
Nitroaromatic compound that’s reduced→ forms ROS → cell death
|
|
Nifurtimox
USE |
ONLY acute T. cruzi infections
(effective against organisms that lack catalase) |
|
Nifurtimox
SE |
Anaphylaxis, (Delayed hypersensitivity)
Peripheral neuropathy |
|
Sodium stibogluconate
MOA |
Inhibits phosphofructokinase → inhibits glycolysis.
|
|
Sodium stibogluconate
USE |
3 types of leishmaniasis
Cutaneous Mucocutaneous Visceral |
|
Sodium stibogluconate
SE |
Cardiac arrhythmias
|
|
Pyrimethamine
MOA |
Inhibits DHFR (dihydrofolate reductase)
→ ↓ tetrahydrofolate → ↓ purines, pyrimidines. |
|
Pyrimethamine
USE |
Drug of choice for T. gondii.
|
|
Pyrimethamine
SE / ANTIDOTE |
Megaloblastic anemia
reversible with leucovorin (antidote) |
|
Ondansetron
MOA |
Blocks 5-HT3 receptors, which contribute to emesis via vagal afferents & area postrema (chemoreceptor trigger zone [CTZ]).
|
|
Ondansetron
USE |
Chemotherapy-induced nausea
Pregnancy-induced hyperemesis Postoperative nausea |
|
Prochlorperazine & Chlorpromazine & Promethazine
CLASS / MOA |
Dopamine receptor antagonists
Blocks D2 receptor at CTZ *Also antihistamine & anticholinergic effects |
|
Prochlorperazine & Chlorpromazine & Promethazine
USE |
General purpose antinauseants, antiemetics
|
|
Prochlorperazine & Chlorpromazine & Promethazine
SE |
Drowsiness
|
|
Droperidol
CLASS / MOA |
Dopamine receptor antagonists
Blocks D2 receptor at CTZ |
|
Droperidol
USE |
Antiemetic in surgical, diagnostic procedures
|
|
Droperidol
SE |
HIGH INCIDENCE OF ALTERING CARDIAC CONDUCTION
|
|
Metoclopramide
MOA AND EFFECTS FOR ANTINAUSEA |
Blocks D2 receptor at CTZ
Also a prokinetic (promotility) agent. ↑ ACh release from enteric neurons by: 1) Suppressing 5-HT3 inhibitory neurons 2) Activating 5-HT4 excitatory neurons |
|
Metoclopramide
USE |
Chemotherapy-induced nausea
GERD (promotility) |
|
Metoclopramide
SE |
Extrapyramidal effects
*Acute dystonia **Tardive dyskinesia-like condition (reversible) |
|
Meclizine & Diphenhydramine
CLASS / MOA |
Antihistamines
Block H1 receptors on vestibular afferents (motion sickness) and in the brain stem |
|
Meclizine & Diphenhydramine
AS A WHOLE THEY ARE USED FOR____ GIVE USE FOR EACH SPECIFICALLY |
Antinauseant
Meclizine = DOC Pregnancy-induced nausea Diphenhydramine = Chemotherapy-induced nausea |
|
Scopolamine
CLASS & USE |
Anticholinergic
MOTION SICKNESS |
|
AS A GENERAL RULE, ANTICHOLINERGIC AGENTS ARE NOT USED FOR THIS TYPE OF NAUSEA
|
NOT FOR CHEMO INDUCED NAUSEA
|
|
Dronabinol
MOA |
δ-9-tetrahydrocannabinol (THC)
CB1 cannabinoid receptors in vomiting center |
|
Dronabinol
USE |
Chemotherapy-induced nausea (prophylaxis)
Stimulates munchies in AIDS patients |
|
Dronabinol
SE |
Central sympathomimetic activity
Tachycardia, marijuana-like highs |
|
Dronabinol IS THIS TYPE OF DRUG
|
MARIJUANA (CANNABIS)
|
|
NAME 2 DRUGS USED IN IRRITABLE BOWEL SYNDROME WHICH IS:
Constipation-predominate |
Dietary fiber
Psyllium |
|
NAME 2 DRUGS USED IN IRRITABLE BOWEL SYNDROME WHICH IS:
Diarrhea-predominate |
Psyllium
Loperamide |
|
NAME 2 CLASSES AND 2 DRUGS IN EACH CLASS USED IN IRRITABLE BOWEL SYNDROME WHICH MOSLTY CAUSES:
Abdominal pain & bloating |
-Antispasmodic Agents
*Dicyclomine *Atropine + Hyoscyamine + Phenobarbital + Scopolamine -Antidepressants *TCA: Amitriptyline *SSRI: Paroxetine |
|
what are the physiological effects of bile acid
|
induce bile flow
feedback inhibition of CE synthesis elimination of CE dispersion/absorption of lipids and fat soluble vitamins |
|
Ursodeoxycholic acid
CLASS |
Bile acid
|
|
Ursodeoxycholic acid
USE |
cholesterol monohydrate gallstone (< 15 mm) dissolution, cholestatic liver disease
works in 40-60% of patients |
|
Uncoated Lipase & Protease
USE |
malabsorption & pain
|
|
Enteric-coated Lipase and Protease
USE / ADVANTAGE |
malabsorption
dissolves farther down in the intestines |
|
name 4 Intraluminal agents to treat diarrhea
|
-Psyllium
-Kaolin -Cholestyramine -Bismuth subsalicylate |
|
Psyllium
MOA |
bulking agent, absorbs water and increases stool bulk
|
|
Psyllium
USE |
constipation,
mild chronic diarrhea |
|
Kaolin
MOA |
Clay that binds water avidly
Also may bind enterotoxins |
|
Kaolin
USE |
Mild diarrhea (symptomatic relief)
|
|
Cholestyramine
MOA |
Anion-exchange resin that binds bile acids, some bacterial toxins
|
|
Cholestyramine
USE |
-Patients with resected distal ileum (< 100 cm) who develop bile salt-induced diarrhea.
-Clindamycin-associated diarrhea -C. difficile-induced mild colitis |
|
why should Cholestyramine not be given in bowel resection greater than 100 cm?
|
will aggravate diarrhea because of bile-salt depletion → steatorrhea.
|
|
Bismuth subsalicylate
MOA / EFFECTS OF EACH COMPONENT |
Reacts with HCl in stomach to form bismuth oxychloride and salicylic acid.
Salicylic acid is absorbed in stomach, Bismuth has antisecretory, anti-inflammatory, antimicrobial effects. |
|
Bismuth subsalicylate
USE |
Traveler’s diarrhea
H. pylori eradication adjunct |
|
Bismuth subsalicylate
SE / WHY |
Dark, black stools; darkening of tongue
(reaction between drug and sulfides produced by bacteria in mouth). |
|
name 2 opioids to treat diarrhea
|
-Loperamide
-Diphenoxylate + Atropine |
|
how do opioids affect diarrhea by acting on the specific receptors
|
-intestinal motility (μ receptors),
-intestinal secretion (δ receptors), -absorption (μ, δ) |
|
Loperamide
effects compared to morphine |
40 to 50 times more potent than morphine as antidiarrheal agent.
|
|
Loperamide
advantage |
DOES NOT penetrate CNS (NO abuse potential),
|
|
Diphenoxylate is structurally related to _____
|
structurally related to meperidine
|
|
Diphenoxylate
effects compared to morphine |
Slightly more potent than morphine as antidiarrheal agent.
|
|
Diphenoxylate
disadvantage |
produce CNS effects (high potential for abuse or addiction)
|
|
this drug is added to Diphenoxylate when treated for diarrhea, WHY?
|
Atropine is added to diphenoxylate to discourage abuse.
|
|
Loperamide
USE |
chronic diarrhea
travelers diarrhea occasional "bouts" of diarrhea |
|
Octreotide
related to ______ |
analog of somatostatin
|
|
Octreotide
USE |
Severe secretory diarrhea caused by metastatic carcinoid tumors that secrete VIP
|
|
VIP secreting tumors found in the:
GI tract are called _______ PANCREASE are called _____ |
GI tract: carcinoid syndrome
Pancreas: Verner-Morrison syndrome or pancreatic cholera |
|
this is defined as the part of food that is resistant to enzymatic digestion (fermentation). this attracts water and increases stool bulk
|
Dietary Fiber
|
|
Psyllium husk
MOA |
undergoes significant fermentation in colon
→ ↑ colonic bacterial mass |
|
Psyllium husk
USE |
Constipation
|
|
Psyllium husk is contraindicated in these pts
|
Contraindicated in patients with obstructive symptoms.
|
|
Methylcellulose & Polycarbophil
MOA |
Poorly fermentable compounds that are able to absorb water and ↑ fecal bulk.
|
|
Methylcellulose & Polycarbophil
USE |
Constipation
|
|
Methylcellulose & Polycarbophil is contraindicated in these pts
|
Contraindicated in patients with obstructive symptoms.
|
|
Docusate (-sodium or -calcium)
MOA |
Anionic surfactants that ↓ surface tension of stool to allow mixing of aqueous & fatty substances → softens stool (easier defecation).
|
|
Docusate (-sodium or -calcium)
USE |
Constipation (low efficacy despite widespread use)
|
|
Mineral oil
EFFECTS |
Softens stool
|
|
Mineral oil is rarely used anymore due to THESE SE
|
↓ Absorption of fat-soluble vitamins
Foreign-body reactions in intestinal mucosa Leakage of oil |
|
GIVE 2 EXAMLES OF SALINE LAXATIVES (osmotically active agent)
|
Magnesium Sulfate
Magnesium Citrate |
|
SALINE LAXATIVES
MOA |
Osmotically-mediated water retention
→ stimulates peristalsis |
|
SALINE LAXATIVES
USE |
Acute evacuation of bowel before diagnostic exams
Parasite elimination adjunct |
|
DO NOT USE SALINE LAXATIVES WITH:
|
Renal insufficiency
Cardiac disease Preexisting electrolyte abnormalities Patients on diuretic therapy |
|
Glycerin
CLASS / MOA |
Nondigestible Alcohols
Hygroscopic agent (rectal lubricant) |
|
Glycerin
USE |
Constipation
|
|
Lactulose
CLASS / MOA |
Nonabsorbable sugar
hydrolyzed in intestine to organic acids → acidify luminal contents→ osmotically draw water into lumen → ↑ colonic propulsive motility |
|
Lactulose
2- USE (also for IM) |
Constipation
Hepatic encephalopathy |
|
Polyethylene glycol
(PEG)-electrolyte solutions MOA |
Long-chain PEGs are poorly absorbed→ osmotically draw water into lumen.
|
|
Polyethylene glycol
(PEG)-electrolyte solutions USE |
Widely used as a cathartic prior to bowel procedures (4 liters over 3-4 hours).
|
|
Bisacodyl
EFFECT |
Induce low-grade inflammation in intestines to ↑ water & electrolyte secretion, ↑ intestinal motility
|
|
Bisacodyl
KINETICS |
Enteric-coated
requires hydrolysis in bowel for activation |
|
Anthraquinones (Cascara & Senna)
MOA / EFFECTS |
Bacterial action in colon activates agents → produce giant migrating colonic contractions, ↑ water & electrolyte secretion
|
|
Ricinoleic Acid (Castor Oil)
MOA |
Castor oil is hydrolyzed in small bowel by lipases into glycerol & ricinoleic acid,
→ ↑ fluid & electrolyte secretion, speeds intestinal transit. |
|
Ricinoleic Acid (Castor Oil) is not used much anymore because ___
|
ricin is a toxic metabolite that has effects on intestinal epithelium, enteric neurons.
|
|
Mesalamine
MOA |
Inhibits cyclooxygenase pathway.
VERY POTENT Scavenger of ROS (especially OH-) |
|
Mesalamine
USE |
Acute mild to moderate ulcerative colitis or Crohn’s disease.
Prophylaxis during remission |
|
Mesalamine
SE |
Nephrotoxicity (serious but very rare)
|
|
Sulfasalazine
KINETICS / MOA |
Mesalamine is main active metabolite, which is linked to sulfapyridine by diazo bond (prevents early absorption of mesalamine). Diazo bond is split by bacterial azoreductases in colon.
|
|
Sulfasalazine
USE |
Acute mild to moderate ulcerative colitis
(NOT Crohn’s disease). Prophylaxis during remission. |
|
Sulfasalazine
SE OF WHICH COMPONENT |
Sulfapyridine component:
Megaloblastic anemia (give folate) Agranulocytosis Drug-induced lupus Steven-Johnson syndrome |
|
Mesalamine & Sulfasalazine
which is better for the treatment of SEVERE IBD? |
NEITHER IS USED IN SEVERE IBD
|
|
name 2 glucocorticoids used in the treatment of SEVER IBD
|
Prednisone
Hydrocortisone |
|
Prednisone & Hydrocortisone
USE |
Severe ulcerative colitis
Severe Crohn’s disease |
|
Cyclosporine
MOA |
Calcineurin inhibitor
Causes pronounced suppression of proinflammatory transcription factors |
|
Cyclosporine
USE |
Acute IBD not responsive to glucocorticoids
(NOT effective for maintenance therapy) |
|
Azathioprine
MOA |
*Converted to 6-mercaptopurine*
Has *several anti-inflammatory properties** (↓ lymphocyte proliferation). |
|
Azathioprine
USE |
IBD long-term maintenance therapy
(↓ requirement for steroids) |
|
Azathioprine
DISADVANTAGE |
limited by slow onset of action
|
|
Methotrexate
EFFECTS |
Cytotoxic agent with pronounced immunosuppressive and anti-inflammatory properties.
|
|
Methotrexate
USE |
Steroid-dependent Crohn’s disease
(NOT ulcerative colitis). |
|
Infliximab
MOA |
Monoclonal Antibody against TNF
(neutralizes TNF activity). |
|
Infliximab
USE / ADVANTAGE |
Severe Crohn’s disease.
(promotes healing of fistulae) |
|
what are the 2 major causes of GI ulcer formation, which is more important
|
decreased mucous (* most imp)
increased acid production |
|
cells of the stomach
what 2 things are produced by parietal cells |
HCL and intrinsic factor
|
|
cells of the stomach
chief cells secrete _____ |
pepsinogen
|
|
secretion of acid requires this type of pump specifically
|
Hydrogen/Potassium ATPase Proton pump
|
|
**GASTRIC ACID SECRETION OCCURS DUE TO THESE 3 ENDOGENOUS SUBSTANCES**
|
*************
ACTEYLCHOLINE GASTRIN HISTAMINE |
|
pepsinogen is a proenzyme that will form _______ in this type of environment. that will combine with acid to form a ______ complex
|
pepsinogen → PEPSIN
in an ACID environment pepsin + acid → PROTEOLYTIC COMPLEX |
|
what 2 features of gastric epithelium helps it to avoid injury from the gastric acid
|
mucous production
rapid and continual cell turnover |
|
what are the 2 mechanisms by which PROSTAGLANDINS protect the GI mucosa
|
inhibits gastric acid production (by parietal cells)
stimulating mucous and bicarb production (in mucous secreting cells) |
|
this causes an inflammatory gastritis and is a MAJOR CONTRIBUTOR TO PEPTIC ULCER DZ
|
H pylori
|
|
this syndrome is manifested as a condition of excessive GASTRIN PRODUCTION WHICH INCREASES HISTAMINE RELEASE AND ESSENTIALLY INCREASED acid production
**GIVE DOC FOR Tx |
Zollinger- Ellison syndrome
DOC = OMEPRAZOLE (-PRAZOLE's) |
|
how is the pain of ulcers typically described
|
burning "Gnawing"
|
|
WHAT IS THE PRIMARY DEFECT IN GERD?
|
DECREASED LOWER ESOPHAGEAL SPHINCTER (LES) PRESSURE
|
|
CIMETIDINE (& ALL -TIDINE's)
CLASS |
Histamine H2 receptor antagonists
|
|
CIMETIDINE (& ALL -TIDINE's)
MOA / EFFECT |
H2 block → ↓ gastric acid secretion (from parietal cells)
|
|
CIMETIDINE (& ALL -TIDINE's)
USE |
Peptic ulcers
GERD |
|
CIMETIDINE
SE |
POTENT P450 INHIBITOR
Maybe antiandrogenic effects → gynecomastia |
|
Omeprazole & Esomeprazole (ALL THE -PRAZOLES)
CLASS |
H+/K+-ATPase Proton pump inhibitors (PPIs)
|
|
Omeprazole & Esomeprazole (ALL THE -PRAZOLES)
MOA / EFFECT |
irreversibly Block proton pump
→ ↓↓↓ gastric acid secretion (effects last long after drug elimination) |
|
Omeprazole & Esomeprazole (ALL THE -PRAZOLES)
USE |
Active ulcers
GERD Zollinger-Ellison syndrome (DOC) H. pylori eradication adjunct |
|
of all the -PRAZOLES which is the only one with significant kinetics?
--> what is it |
Omeprazole is P450 inhibitor
|
|
name 2 ULCER DRUGS WHICH INHIBIT P450
|
CIMETIDINE
OMEPRAZOLE |
|
WHAT IS THE TREATMENT STRATEGY TO ERADICATE H. PYLORI?
|
PPI + 2 ANTIBIOTICS FROM THIS SELECTION: MCAT
metronidazole clarithromycin amoxicillin tetracycline |
|
Misoprostol
CLASS |
Prostaglandin ANALOG
|
|
Misoprostol
MOA / EFFECT |
Prostaglandin E2, I2 receptor agonist.
↓ cAMP → ↓ acid secretion. Also ↑ mucous, bicarbonate production. |
|
Misoprostol
ONLY USED FOR ______ |
NSAID-induced gastric ulcers ONLY
|
|
Misoprostol
MAIN SE |
ABORTION
|
|
Dicyclomine
CLASS / SIMILAR TO _____ |
Antimuscarinic agent
atropine like |
|
Dicyclomine
MOA / EFFECT |
Block muscarinic receptors
→ ↓ gastric acid secretion |
|
Dicyclomine
USE |
Adjunct in peptic ulcer treatment
(rarely used) |
|
Dicyclomine
SE |
Atropine-like adverse effects
|
|
Antacids
ADVANTAGE / DISADVANTAGE |
FASTEST TO RELIEVE PAIN
BUT SHORT ACTING |
|
what are the 4 main metals used in antacids?
|
Al - (OH)3,
Mg - (OH)2 Ca - CO3, Na - HCO3 |
|
antacids
MOA |
react with gastric acid to produce water and salt.
Also reduce pepsin activity by ↑ pH. |
|
ANTACIDS
USE |
Promote healing of gastric ulcers
Relieve symptoms of GERD |
|
ANTACIDS
KEY KINETICS |
SINCE THEY ↑pH THEY WILL
↓ ABSORPTION OF WEAK ACIDS AND ↑ ABSORPTION OF WEAK BASES |
|
WHAT TIMING SHOULD YOU NOTIFY YOUR PATIENTS TALKING ANTACIDS WITH ANY OTHER DRUG?
|
Take antacids 2 hours before or after other drugs
|
|
WHICH 2 METALS HAVE THE MOST SIGNIFICANT SE POTENTIAL OF THE ANTACIDS
--> GIVE EFFECT |
Al(OH)3: constipation
Mg(OH)2: diarrhea |
|
Sucralfate
MOA / EFFECT |
(sulfated sucrose) creates gel barrier that impairs acid diffusion
coats ulcer surface and enhances healing |
|
Sucralfate
requires ____ for activation do not use with _____ |
Requires acid to be activated
CAN NOT be taken with antacid |
|
Colloidal bismuth
MOA |
neutralizes acid, ↑ mucous, bicarbonate production
|
|
Colloidal bismuth
SE |
BLACK TONGUE
BLACK STOOL INCREASED BLEEDING TIME |
|
Metoclopramide
CLASS |
Promotility agent
|
|
Metoclopramide
MOA / EFFECT for GERD |
↑ ACH release from enteric neurons =↑ GI motility and INCREASES LES PRESSURE
(also blocks D2 receptors) |
|
Metoclopramide
USE |
GERD
(alternative to PPIs, H2 blockers) Also antiemetic |
|
why has the use of Metoclopramide been drastically reduced?
|
because of the D2 antagonism (similar to typical antipsychotics)
TARDIVE DYSKINESIA HAS BEEN NOTED IN THEIR SE |
|
HOW ARE NSAIDS AND CORTICOSTEROIDS INVOLVED WITH ACID PRODUCTION?
|
NSAIDS AND CORTICOSTEROIDS
block phospholipase A2 so less PG's produced allowing for increased acid production |
|
how does the efficacy of PPI compare to H2 receptor blockers (cimetidine)?
--> why |
PPI's are much more efficacious
they block acid production from all 3 inputs ACH, Histamine and Gastrin |
|
define:
p pc PO PR prn |
p= after
pc= after meals PO= by mouth PR= per rectum prn= when needed |
|
define:
q qam, om qh, q1h q2h, q3h |
q = every
qam, om = every morning qh, q1h = every hour q2h, q3h =every 2 hrs, every 3 hrs |
|
define:
qid qod qs |
qid = 4 times per day
qod = every other day qs = sufficient quantity |
|
who can prescribe medications?
|
all DO's and MD's, and in some states:
pharmacists, NP, PA, optometrists, dentists (usu they are limited to what classes can be written) |
|
what should be written after the sig: notation on a script
|
how to take the medication (ie take 1 tab twice daily) and the use of the medicine (for blood pressure control)
|
|
WHAT IS THE POTENTIAL HEALTH BENEFIT IN HUMANS OF:
Black cohosh root |
↓ Menopausal symptoms
|
|
WHAT IS THE POTENTIAL HEALTH BENEFIT IN HUMANS OF:
Echinacea |
↑ Immune function (colds)
|
|
WHAT IS THE POTENTIAL HEALTH BENEFIT IN HUMANS OF:
Garlic |
↓ Cholesterol & lipids, ↓ HTN
|
|
WHAT IS THE POTENTIAL HEALTH BENEFIT IN HUMANS OF:
Ginko biloba leaf |
Improve cognition (studies with Alzheimer’s)
|
|
WHAT IS THE POTENTIAL HEALTH BENEFIT IN HUMANS OF:
Ginseng root |
↓ Fatigue
|
|
WHAT IS THE POTENTIAL HEALTH BENEFIT IN HUMANS OF:
Saw palmetto berry |
↓ BPH symptoms
|
|
WHAT IS THE POTENTIAL HEALTH BENEFIT IN HUMANS OF:
St. John’s wort |
Antidepressant (common use in Europe)
|
|
WHAT IS THE POTENTIAL HEALTH BENEFIT IN HUMANS OF:
Valerian root |
Improves sleep quality
|
|
WHAT IS THE POTENTIAL HEALTH BENEFIT IN HUMANS OF:
Soy |
↓ Cholesterol & lipids
|
|
WHAT IS THE POTENTIAL HEALTH BENEFIT IN HUMANS OF:
Glucosamine & Chondroitin |
Attenuates osteoarthritis
|
|
WHAT IS THE POTENTIAL HEALTH BENEFIT IN HUMANS OF:
Creatine |
↑ Muscle mass, strength, performance during short bouts of intense exercise
|
|
Saw palmetto berry
MOA / SIMILAR ACTION OF ____ |
Anti-androgenic
inhibits 5α-reductase ACTS like FINESTERIDE |
|
St. John’s wort
MOA / SIMILAR ACTION OF ___ |
Proposed to ↑ 5-HT
SIMILAR TO AN SSRI |
|
the DSHEA was created by FDA what actions did they create for herbal products
|
DSHEA requires:
-no proof of efficacy, -no proof of safety, -no sets for quality control -products may not promise a specific cure, but they can make statements of benefits to use |
|
what are the 5 main signs of chronic lead poisoning?
|
lead colic
lead palsy wrist drop foot drop lead encephalopathy |
|
what classic sign is seen on xray of lead poisoning
|
lead lines
|
|
hematologic signs of lead poisoning
|
basophillic stippling
sideroblastic (hypochromic, microcytic) anemia |
|
lead inhibits heme synthesis:
which 2 enzymes are actually inhibited in the pathway, and GIVE THE MOLECULE WHICH ACCUMULATES FOR EACH |
AMINOLEVULINATE DEHYDRATASE
→ increase Delta-ALA FEROCHELATASE →PROPOPORPHYRIN |
|
WHAT IS THE TX OF LEAD POISONING
|
DIMERCAPROL
SUCCIMER (for children) |
|
give the MOST COMMON SOURCE FOR:
METHYLMERCURY (organic Hg) & MERCURY VAPOR |
methylmercury
→FISH mercury vapor →Dental amalgams |
|
because of the reaction with _____ Arsenic is found here in HIGH concentrations
|
rxn with sulfhydryls in keratin
accumulate in skin and nails |
|
what is the major target of chronic cadmium poisoning
|
kidney
|
|
how are most pts exposed to iron?
|
Acute exposure from accidental poisoning with ferrous salts
|
|
Symptoms of Iron toxicity:
when is it seen s/sx when does death occur? |
seen w/in 30 minutes
Severe GI upset: BLOODY VOMIT AND BLOODY DIARRHEA, ABD PAIN death w/in 6hrs OR 12-24 hrs |
|
what is Tx for Iron toxicity
|
DEFEROXAMINE
|
|
WHAT IS USE OF HEAVY METAL ANTAGONIST (CHELATOR):
Dimercaprol |
MANY MANY DIFFERENT TOXINS
is a good 1st choice |
|
WHAT IS USE OF HEAVY METAL ANTAGONIST (CHELATOR):
Succimer |
Lead poisoning in children
|
|
WHAT IS USE OF HEAVY METAL ANTAGONIST (CHELATOR):
Penicillamine |
Copper poisoning (Wilson’s disease)
|
|
WHAT IS USE OF HEAVY METAL ANTAGONIST (CHELATOR):
Deferoxamine |
Iron poisoning
|
|
** WHICH TOPICAL VEHICLE IS:
MOST HYDRATING MOST DRYING |
Ointments: most hydrating
Soaks: least hydrating (most drying) |
|
Neosporin
(Triple antibotic ointment [TAO]) OTC or Rx COMPOSITION USE |
OTC
Neomycin + Bacitracin + Polymyxin B. Use: minor cuts, scrapes, burns |
|
Neosporin G
OTC or Rx COMPOSITION USE |
Rx
Neomycin + Gramicidin Use: minor cuts, scrapes, burns |
|
Mupirocin
OTC or Rx USE |
Rx.
Use: S. pyogenes impetigo |
|
Povidone-iodine
OTC or Rx USE |
OTC
Use: wound cleansing |
|
Hexachlorophene
OTC or Rx USE |
Rx solution.
Use: wound cleansing |
|
Hexachlorophene
Adverse effect: |
CNS toxicity
|
|
Chlorhexidine
OTC or Rx USE |
OTC solution
Use: wound cleansing |
|
Name 1 of each:
High Intermediate Low -Potency topical glucocorticoids |
H -Betamethasone dipropionate
I - Triamcinolone acetate L- Hydrocortisone |
|
WHAT ARE THE
LOCAL & SYSTEMIC ADVERSE EFFECTS OF topical glucocorticoids |
Local: Skin atrophy, acneiform eruptions, hypopigmentation.
Systemic: Suppression of HPA axis, growth retardation in small children. |
|
Retinoids: basically _____ compounds
give the major effects |
Vit A compounds
influence cellular proliferation, differentiation, inflammation, sebum production; mediated through nuclear acid receptors (RARs) → enhance transcription |
|
Tretinoin
MOA |
↓ Hyperkeratinization → ↓ microcomedone formation (initial acne lesion).
|
|
Tretinoin
USE |
Topical use: Acne
|
|
Tretinoin
SE / CI IN THESE PTS |
Erythema & Photosensitivity (greater risk of sunburn)
NEVER USE IN A PREGNANT PT!!! |
|
Isotretinoin
MOA |
decreases:
1) Sebum synthesis, 2) Propionibacterium acnes (causes acne inflammation), 3) Microcomedone formation |
|
Isotretinoin
USE |
Oral use: Severe nodular acne & acne unresponsive to oral antibiotics
|
|
Isotretinoin
TOXICITY (SE) |
VERY VERY TERATOGENIC
Mucous membrane dryness, dry eyes, conjunctivitis Photosensitivity Hyperlipidemia Depressive episodes, suicidal tendencies |
|
Retinoic acid
IS USED FOR THESE PROCEDURES |
Skin peels (removes the top layer of skin)
|
|
Etretinate
MOA |
Normalizes expression of keratins
|
|
Etretinate
USE / T 1/2 |
ORALLY FOR Inflammatory psoriasis
T 1/2 = 100 DAYS |
|
Etretinate
SE |
Hair loss, sticky skin, easy bruising, liver function abnormalities
TERATOGENIC |
|
Methoxsalen
COMPONENT OF ____ THERAPY MOA |
PUVA THERAPY
MOA: ↑ melanogenesis in normal skin. |
|
Methoxsalen
SE EARLY & WITH CHRONIC USE |
EARLY: blistering, painful erythema, cataract formation, liver dysfunction
Chronic effects within skin: photo-aging, non-melanoma skin cancer (10x incidence of squamous cell carcinoma) |
|
Calcipotriene
MOA |
Vitamin D analog (modulates transcription in epidermal keratinocytes)
|
|
Calcipotriene
USE |
Psoriasis topical therapies
|
|
Anthralin
MOA |
MOA: ↓ DNA synthesis (intercalation), ↓ mitochondrial activity, ↓ ROS formation
|
|
Anthralin
USE / SE |
Psoriasis topical therapies
Black staining & irritation of skin |
|
Coal Tar
MOA / USE |
MOA: ↓ DNA synthesis
Psoriasis topical therapies |
|
Lactic acid, Glycolic acid & Salicylic acid
MOA / USE |
MOA: eats away at the skin
Use: hyperkeratosis, scaling cutaneous eruptions |
|
Podophyllin resin
USE / SE |
Use: genital warts.
SE: Serious neuropathy & death from use of large amounts on multiple lesions (take warts off one at a time). |
|
Lindane
MOA / USE |
Stimulates nervous system → death of arthropods
head lice, crab lice & their ova (scabies) |
|
Calamine
COMPOSED OF |
Zinc oxide + ferric oxide
|
|
Domeboro
COMPOSED OF |
Aluminum sulfate + calcium acetate
|